Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$105.84
-$0.92(-0.88%)
At close: 4:00 PM EDT
$105.84
-$0.92(-0.88%)
Day’s Range― - ―
52-Week Range$32.22 - $117.88
Previous CloseN/A
Volume827.63K
Average Volume (3M)699.18K
Market Cap
$5.42B
Enterprise Value$4.58K
Total Cash (Recent Filing)$886.81M
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding55,934,380
10 Day Avg. Volume906,941
30 Day Avg. Volume699,177
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$142.17Price Target Upside34.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.8
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Expanding Capital BaseMinimal debt reduces financial risk and interest burdens, preserving flexibility while Dianthus funds clinical development. The expanded equity and asset base can support continued research and operations, giving the company a stronger foundation than a similarly loss-making biotech with heavy leverage.
Promising Clinical Program ProgressThe interim Phase 3 response signal supports meaningful progress for the lead program and could strengthen the path toward a future therapy for severe autoimmune disease. Continued clinical validation would improve commercial credibility and create a clearer basis for advancing the complement-focused pipeline.
Strong Gross Economics On Existing RevenueVery high gross margins indicate that the limited revenue generated has strong underlying economics before operating investment. If clinical programs eventually produce recurring product or partnership revenue, this margin profile could provide substantial contribution toward research spending and future corporate overhead.
Bears Say
Escalating Cash BurnCash usage is rising materially as development spending continues, increasing the capital required to reach clinical and regulatory milestones. Persistent negative operating and free cash flow can reduce financial flexibility over time and may force additional funding before the business generates dependable operating cash.
Persistent Operating Losses And Limited ScaleThe company has not yet demonstrated an operating model capable of converting its programs into sustainable earnings. Substantial losses and limited revenue scale leave results highly dependent on successful development progress, while continued investment can keep profitability distant even if gross margins remain high.
Pre-commercial Financing DependenceWithout marketed products or recurring commercial revenue, Dianthus must rely on capital markets and similar financing activities to fund operations. This dependence can increase dilution risk and makes long-term execution more sensitive to the timing and availability of external funding.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $32.22 and its highest was $117.88 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $5.42B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.846 by -$0.054.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.94.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 55,934,380 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.846. Following the earnings report the stock price went up 1.902%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.17 (34.32% Upside)
$142.17 (34.32% Upside)
Blogger Sentiment
Neutral
DNTH Sentiment 50%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 19.3%
Last 30 Days ▼ 19.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
272.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$142.17
▲(34.32% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.15% Insiders
25.53% Mutual Funds
53.53% Other Institutional Investors
7.99% Public Companies and
Individual Investors